Report Events

[Registration Closed] AMR Alliance Japan Urgent Forum The Stable Supply of Antimicrobials and Crisis in the Antimicrobial Market A Call for Global Public-Private Cooperative Action from the G20 (October 7, 2019)

AMR Alliance Japan Urgent Forum
The Stable Supply of Antimicrobials and Crisis in the Antimicrobial Market
A Call for Global Public-Private Cooperative Action from the G20

Every year, approximately 700,000 people die globally from antimicrobial resistance (AMR) related causes. Without serious action on this issue, it is estimated that as many as 10 million people could die annually due to AMR by 2050. To help address this issue, in July 2019, AMR Alliance Japan released AMR Alliance Japan Policy Recommendations: The Japanese Government’s Role in Promoting AMR Countermeasures. These recommendations lay out seven concrete themes for action on AMR, including the further promotion of antimicrobial stewardship, the stable supply of antimicrobials, and the creation of incentive models to promote antimicrobial research and development.

Proper antimicrobial stewardship is vital to the fight against AMR and relies on the stable supply of antimicrobials. However, problems have arisen recently related to the supply of antimicrobials in Japan, threatening efforts to treat infectious diseases and prevent infections before and after surgeries. Because pharmaceutical manufacturing is global, relying on production centers located all across the world, the resolution of antimicrobial supply issues is not possible through the efforts of one country alone. Furthermore, this issue has arisen in the context of a worldwide crisis in the antimicrobial market. The profitability of antimicrobials and the predictability of the market are decreasing, making it challenging for pharmaceutical companies to research and develop new pharmaceuticals or ensure the stable supply of existing antimicrobial products. Solutions to structural issues in the antimicrobial market are urgently needed from the perspective of preventing the further spread of AMR in the future.

Within the G20 Osaka Leaders’ Declaration released in June 2019, heads of state from around the world communicated their commitment to global action on AMR based on a One Health Approach. This Declaration included a call for further action “should be taken to promote stewardship of and access to antimicrobials.” Accordingly, it is expected that the G20 Health Ministers’ Meeting scheduled for October 2019 will discuss concrete actions for AMR.

This AMR Alliance Japan Urgent Forum aims to support such discussion at the G20 Health Ministers’ Meeting by debating possibilities for urgent action on the stable supply of antimicrobials and antimicrobial research and development.

  • Date and Time: Monday, October 7, 2019; 15:00-17:05
  • Venue: International House Iwasaki Koyata Memorial Hall (5-11-16 Roppongi, Minato-ku, Tokyo)
  • Organizer: AMR Alliance Japan / Health and Global Policy Institute (HGPI)
  • Attendees: Policymakers, relevant ministry officials, academic and private sector representatives, people involved with the G20, etc. (by invitation only / approx. 80 attendees)
  • Program: (Discussion panel participants listed in no particular order)

14:40   Doors Open
15:00-15:05 Explanatory Introduction

  • Ryoji Noritake (CEO, Board Member, HGPI)

15:05-15:10 Welcome Remarks

  • Masaki Yoshida (Professor, Infection Diseases and Infection Control, The Jikei University Hospital)

15:10-15:25 Presentation 1 – The Stable Supply of Antimicrobials: Chaos at Clinical Facilities

  • Tetsuya Matsumoto (Senior Professor, Department of Infectious Diseases, International University of Health and Welfare Graduate School of Medicine)

15:25-15:40 Presentation 2 – The G20 as an Opportunity to Think about Global Action on the Supply of Antimicrobials

  • Yoshiaki Gu (Chief, Information and Education Division, AMR Clinical Reference Center, National Center for Global Health and Medicine)

15:25-15:40 Presentation 3 – Recent Global Trends and Expectations for Japanese Leadership on AMR Countermeasures

  • Jeremy Knox (Wellcome Trust, Drug-Resistant Infections Programme, Policy and Advocacy Lead)

15:40-16:55 Panel Discussion – Measures to Ensure the Stable Supply of Antimicrobials


  • Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
  • Eiji Hinoshita (Director, Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare)
  • Hajime Inoue (Director General, Bureau of Strategic Planning, National Center for Global Health and Medicine)
  • Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)


  • Tomohito Shibata (AMR Alliance Japan Secretariat / Senior Associate, HGPI)

16:55-17:05 Closing Remarks

  • Keizo Takemi (Member, House of Councillors) 

Notes: Program is subject to change. Simultaneous English-Japanese Interpretation will be provided.

  • This Forum will make use of the Chatham House Rule. Information on which panelist said which comment will not be made public following the meeting. AMR Alliance Japan asks for your understanding on this rule, which is being adopted to promote open communication.


About AMR Alliance Japan – – – – – – – – – – – – – –

AMR Alliance Japan is an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR.

The Alliance was established in November 2018 by a coalition of Japanese academic societies working in infectious disease medicine and pharmaceutical and medical technology companies. Current members as of August 2019 include, in alphabetical order: The Japanese Association for Infectious Diseases, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Medical Mycology, The Japanese Society for Pediatric Infectious Diseases, The Japanese Society of Chemotherapy, The Japanese Society of Pharmaceutical Healthcare and Sciences, The Japanese Society of Therapeutic Drug Monitoring, The Japan Pharmaceutical Manufacturers Association, MSD K.K., Nippon Becton, Dickinson and Company, Ltd., Pfizer Japan Inc., The Pharmaceutical Society of Japan, Shionogi & Co., Ltd., and Shiro Shoni Iryo Mamoro Kodomo-tachi no Kai. The Health and Global Policy Institute (HGPI) serves as Secretariat of the Alliance

– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –

Back to Events